国药一致(000028) - 2024 Q4 - 年度业绩

Financial Performance - Total revenue for 2024 was CNY 74.38 billion, a decrease of 1.46% year-on-year[3] - Operating profit fell to CNY 5.73 billion, down 76.76% compared to the previous year[3] - Net profit attributable to shareholders decreased to CNY 6.42 billion, a decline of 59.83% year-on-year[3] - Basic earnings per share dropped to CNY 1.15, reflecting a 59.93% decrease from the prior year[3] - The weighted average return on equity decreased by 5.89 percentage points to 3.67%[3] Segment Performance - The distribution segment achieved revenue of CNY 52.98 billion, an increase of 1.98% year-on-year[6] - The retail segment reported revenue of CNY 22.36 billion, a decline of 8.41% year-on-year[6] Asset and Equity - Total assets at the end of the reporting period were CNY 475.56 billion, a slight decrease of 0.03%[3] - Shareholders' equity attributable to the parent company increased by 1.46% to CNY 176.70 billion[3] Impairment - The company recognized an impairment provision of CNY 970 million for goodwill and intangible assets, impacting net profit by CNY 561 million[6]